These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1342026)

  • 1. Magnetic fields in the treatment of Parkinson's disease.
    Sandyk R; Anninos PA; Tsagas N; Derpapas K
    Int J Neurosci; 1992 Mar; 63(1-2):141-50. PubMed ID: 1342026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
    Sandyk R
    Int J Neurosci; 1992 Mar; 63(1-2):137-40. PubMed ID: 1342025
    [No Abstract]   [Full Text] [Related]  

  • 3. Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon.
    Sandyk R
    Int J Neurosci; 1992 Sep; 66(1-2):97-106. PubMed ID: 1304575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications.
    Sandyk R
    Int J Neurosci; 1994; 74(1-4):191-201. PubMed ID: 7928105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weak magnetic fields antagonize the effects of melatonin on blood glucose levels in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1993 Jan; 68(1-2):85-91. PubMed ID: 8063518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's disease.
    Sandyk R; Derpapas K
    Int J Neurosci; 1993; 69(1-4):167-83. PubMed ID: 8083004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
    Fraix V; Pollak P; Van Blercom N; Xie J; Krack P; Koudsie A; Benabid AL
    Neurology; 2000 Dec; 55(12):1921-3. PubMed ID: 11134399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of micrographia in Parkinson's disease by application of picoTesla range magnetic fields.
    Sandyk R; Iacono RP
    Int J Neurosci; 1994 Jul; 77(1-2):77-84. PubMed ID: 7989163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Variance in effects of subthalamic nucleus stimulation].
    Okiyama R; Yokochi F; Taniguchi M; Takahashi H; Hasegawa N; Hamada I
    No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.